Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today announced presentations of new clinical data from studies of zorevunersen at the 36th International Epilepsy Congress (IEC), taking place August 30 – September 3, 2025 in Lisbon, Portugal. Zorevunersen, an investigational antisense oligonucleotide,
Related Questions
How will the upcoming clinical data presentations at the IEC affect the short‑term price movement of Biogen (BIIB) and Stoke Therapeutics (STOK) stocks?
What are the anticipated regulatory milestones and timeline for zorevunersen based on these new data, and how might they influence market valuation?
How does zorevunersen's efficacy and safety profile compare to existing and pipeline treatments for Dravet syndrome, and what competitive advantage could it provide?